CAHNEUTRAL

CAH EV/EBITDA Analysis

14.4x

Higher than 47% of Healthcare sector peers

Updated 5h ago·SEC filings & market data

Key Takeaway

Cardinal Health’s EV/EBITDA of 15.2x means the company’s total value (market cap plus debt minus cash) equals 15.2 times its annual earnings before interest, taxes, depreciation, and amortization — a common way to gauge if a stock is cheap or expensive.

Sector Performance

47th percentile

CAH

14.4x

Sector Median

15.7x

Sector Avg

29.2x

Prior Period

15.2x(Aug 2026)

↑ Improving

📊

Deep Analysis

At 15.2x, it sits just below the healthcare sector median of 16.1x, placing it in the 47th percentile among peers, so it is slightly cheaper than the typical comparable company. The year-over-year figure is not available, but quarter over quarter the multiple rose 2.5%, from 14.8x to the current 15.2x. Because the valuation is modest relative to peers yet moving upward, this combination points to steady but limited upside potential rather than a bargain or a bubble. The higher multiple appears to be driven by recent earnings changes or market sentiment, not enough to mark a clear risk shift. This metric supports the NEUTRAL verdict, as the level and trend align with an average-risk, average-return profile.

Frequently Asked Questions

What does the EV/EBITDA tell investors about CAH?

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.

How is the EV/EBITDA calculated?

EV/EBITDA is calculated as: Enterprise Value / EBITDA.

How does CAH's EV/EBITDA compare to its sector?

CAH's EV/EBITDA of 14.4x compares to a Healthcare sector median of 15.7x, placing it in the 47th percentile.

Who are CAH's closest peers by EV/EBITDA?

The closest Healthcare peers by EV/EBITDA include: RVTY (17.0x), DGX (14.3x), AMGN (14.0x), ALGN (13.5x), ABT (19.5x).

📚

Learn More About EV/EBITDA

EV/EBITDA Explained: The Valuation Metric Pro Investors Actually Use

Learn what EV/EBITDA is, why it beats P/E for capital-heavy companies, typical sector ranges, and key limitations every serious investor should know.

The Formula

Enterprise Value / EBITDA

Why It Matters

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.